FDA’s Drug Safety Newsletter Exemplifies Communication Challenge
Executive Summary
The second edition of FDA's Drug Safety Newsletter illustrates trade-offs that the agency must make as it offers information to health care professionals
You may also be interested in...
FDA Safety Pilot Prompts SNRI Relabeling; “Too Soon To Tell” Patient Impact
FDA's pilot program to conduct post-market safety reviews of new molecular entities has catalyzed labeling changes for Lilly's Cymbalta, but its impact on patient safety remains uncertain
FDA Faces “Daunting” Mission As It Partners With Doctors For Safe Rx Use
One of FDA's mantras has been that is does not regulate the practice of medicine, and while the agency remains committed to that doctrine, it is now trying to find ways to better influence how doctors prescribe and discuss drugs through its "Safe Use" initiative
FDA’s “Drug Safety Newsletter” Offers Doctors Quarterly Updates On Risks
FDA's inaugural issue of its "Drug Safety Newsletter" suggests the agency will use the publication to remind doctors of potential products rather than be a primary forum for new information